ONO 6126
Alternative Names: DE-103; ONO-6126Latest Information Update: 25 Mar 2009
At a glance
- Originator Ono Pharmaceutical
- Developer Santen Pharmaceutical
- Class Anti-inflammatories; Antiasthmatics; Bronchodilators
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic conjunctivitis; Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 23 May 2008 Phase-II clinical trials in Allergic conjunctivitis in Japan (Ophthalmic)
- 30 Apr 2006 Discontinued - Phase-II for Chronic obstructive pulmonary disease in North America (PO)
- 28 Mar 2006 ONO 6126 has been licensed to Santen Pharmaceutical for ophthalmic use in Japan